Phreesia Competitors

Phreesia (NYSE:PHR) and Nielsen (NYSE:NLSN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares Phreesia and Nielsen's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are owned by institutional investors. 28.2% of Phreesia shares are owned by insiders. Comparatively, 0.4% of Nielsen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Phreesia and Nielsen's gross revenue, earnings per share (EPS) and valuation.

Phreesia has higher earnings, but lower revenue than Nielsen. Phreesia is trading at a lower price-to-earnings ratio than Nielsen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Phreesia has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Nielsen has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Phreesia and Nielsen, as reported by MarketBeat.com.

Phreesia currently has a consensus target price of $53.6429, suggesting a potential upside of 1.44%. Nielsen has a consensus target price of $24.00, suggesting a potential downside of 6.14%. Given Phreesia's stronger consensus rating and higher possible upside, analysts plainly believe Phreesia is more favorable than Nielsen.

Summary

Phreesia beats Nielsen on 8 of the 14 factors compared between the two stocks.

Phreesia (NYSE:PHR) and Shift4 Payments (NYSE:FOUR) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Phreesia and Shift4 Payments' net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are held by institutional investors. Comparatively, 33.4% of Shift4 Payments shares are held by institutional investors. 28.2% of Phreesia shares are held by company insiders. Comparatively, 12.2% of Shift4 Payments shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phreesia and Shift4 Payments' gross revenue, earnings per share and valuation.

Shift4 Payments has lower revenue, but higher earnings than Phreesia.

Analyst Ratings

This is a breakdown of current ratings and target prices for Phreesia and Shift4 Payments, as provided by MarketBeat.

Phreesia currently has a consensus price target of $53.6429, suggesting a potential upside of 1.44%. Shift4 Payments has a consensus price target of $66.00, suggesting a potential downside of 34.91%. Given Phreesia's stronger consensus rating and higher possible upside, equities research analysts clearly believe Phreesia is more favorable than Shift4 Payments.

Summary

Phreesia beats Shift4 Payments on 6 of the 9 factors compared between the two stocks.

Phreesia (NYSE:PHR) and Concentrix (NASDAQ:CNXC) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Phreesia and Concentrix's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are held by institutional investors. 28.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phreesia and Concentrix's gross revenue, earnings per share and valuation.

Concentrix has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than Concentrix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Phreesia and Concentrix, as provided by MarketBeat.

Phreesia currently has a consensus price target of $53.6429, suggesting a potential upside of 1.44%. Concentrix has a consensus price target of $122.50, suggesting a potential downside of 20.45%. Given Phreesia's higher possible upside, equities research analysts clearly believe Phreesia is more favorable than Concentrix.

Summary

Concentrix beats Phreesia on 8 of the 13 factors compared between the two stocks.

Phreesia (NYSE:PHR) and Fiverr International (NYSE:FVRR) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Phreesia and Fiverr International's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are held by institutional investors. Comparatively, 57.9% of Fiverr International shares are held by institutional investors. 28.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phreesia and Fiverr International's gross revenue, earnings per share and valuation.

Phreesia has higher revenue and earnings than Fiverr International. Fiverr International is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Phreesia has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Fiverr International has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Phreesia and Fiverr International, as provided by MarketBeat.

Phreesia currently has a consensus price target of $53.6429, suggesting a potential upside of 1.44%. Fiverr International has a consensus price target of $222.1667, suggesting a potential downside of 1.98%. Given Phreesia's stronger consensus rating and higher possible upside, equities research analysts clearly believe Phreesia is more favorable than Fiverr International.

Summary

Phreesia beats Fiverr International on 8 of the 14 factors compared between the two stocks.

Phreesia (NYSE:PHR) and Ritchie Bros. Auctioneers (NYSE:RBA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Phreesia and Ritchie Bros. Auctioneers' net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are held by institutional investors. Comparatively, 80.3% of Ritchie Bros. Auctioneers shares are held by institutional investors. 28.2% of Phreesia shares are held by company insiders. Comparatively, 0.8% of Ritchie Bros. Auctioneers shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phreesia and Ritchie Bros. Auctioneers' gross revenue, earnings per share and valuation.

Ritchie Bros. Auctioneers has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than Ritchie Bros. Auctioneers, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Phreesia has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Ritchie Bros. Auctioneers has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Phreesia and Ritchie Bros. Auctioneers, as provided by MarketBeat.

Phreesia currently has a consensus price target of $53.6429, suggesting a potential upside of 1.44%. Ritchie Bros. Auctioneers has a consensus price target of $58.9167, suggesting a potential downside of 5.63%. Given Phreesia's stronger consensus rating and higher possible upside, equities research analysts clearly believe Phreesia is more favorable than Ritchie Bros. Auctioneers.

Summary

Ritchie Bros. Auctioneers beats Phreesia on 8 of the 14 factors compared between the two stocks.

Phreesia (NYSE:PHR) and CDK Global (NASDAQ:CDK) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Phreesia and CDK Global's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are held by institutional investors. Comparatively, 82.2% of CDK Global shares are held by institutional investors. 28.2% of Phreesia shares are held by company insiders. Comparatively, 0.5% of CDK Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phreesia and CDK Global's gross revenue, earnings per share and valuation.

CDK Global has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than CDK Global, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Phreesia has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, CDK Global has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Phreesia and CDK Global, as provided by MarketBeat.

Phreesia currently has a consensus price target of $53.6429, suggesting a potential upside of 1.44%. CDK Global has a consensus price target of $64.75, suggesting a potential upside of 19.80%. Given CDK Global's stronger consensus rating and higher possible upside, analysts clearly believe CDK Global is more favorable than Phreesia.

Summary

CDK Global beats Phreesia on 9 of the 14 factors compared between the two stocks.